"The U.S. Food and Drug Administration today allowed marketing of the Eclipse System for the treatment of fecal incontinence (FI) in adult women.
Fecal incontinence is the inability to control bowel movements and is a common problem, espec"...
Adverse experiences with SUCRAID in clinical trials were generally minor and were frequently associated with the underlying disease.
In clinical studies of up to 54 months duration, physicians treated a total of 52 patients with SUCRAID. The adverse experiences and respective number of patients reporting each event (in parenthesis) were as follows: abdominal pain (4), vomiting (3), nausea (2), diarrhea (2), constipation (2), insomnia (1) headache (1) nervousness (1) and dehydration (1).
Note: diarrhea and abdominal pain can be a part of the clinical presentation of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).
One asthmatic child experienced a serious hypersensitivity reaction (wheezing) probably related to sacrosidase (see WARNINGS). The event resulted in withdrawal of the patient from the trial but resolved with no sequelae.
Read the Sucraid (sacrosidase oral solution) Side Effects Center for a complete guide to possible side effects
Neither drug-drug nor drug-food interactions are expected or have been reported with the use of SUCRAID. However, SUCRAID should not be reconstituted or consumed with fruit juice, since its acidity may reduce the enzyme activity.
Last reviewed on RxList: 6/6/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Sucraid Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.